Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)

NCT06011577 is registered in ClinicalTrials.gov with Levomecor Inc. as lead sponsor.

NCT NCT06011577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06011577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
Lead sponsor
Levomecor Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 17, 2023
Completion date
December 19, 2024
Enrollment
27 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

depression, major depressive disorder